THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. LICENSE AND COLLABORATION AGREEMENT by and...Trademark Assignment Agreement • November 6th, 2013 • Pozen Inc /Nc • Pharmaceutical preparations • New York
This license and collaboration agreement (“Agreement”) is made and entered into as of September 3, 2013 (the “Effective Date”) and shall be effective on the Effective Date (as defined herein), by and between POZEN INC., a Delaware corporation having offices at 1414 Raleigh Road, Suite 400, Chapel Hill, North Carolina (“POZEN”), and sanofi-aventis U.S. LLC, a Delaware limited liability company having an office at 55 Corporate Drive, Bridgewater, New Jersey (“Licensee”). POZEN and Licensee each may be referred to herein individually as a “Party,” or collectively as the “Parties.”
AMENDMENT NO. 3 TO THE COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • November 6th, 2013 • Pozen Inc /Nc • Pharmaceutical preparations
This Amendment No. 3 to the Collaboration and License Agreement (this “Amendment No. 3”) is made effective as of September 16, 2013 (the “Amendment
